Table 5.
Alignment of the amino acid residues defining the neutralization domains of VP7 (7-1a, 7-1b, and 7–2) between RotaTeq™ G2 component and G2 strains DS-1, TB-Chen, MMC88, and 16 G2P[4] RVA strains in Bangladesh.
| RVA strain | 7-1a |
7-1b |
7-2 |
||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 87 | 91 | 94 | 96 | 97 | 98 | 99 | 100 | 104 | 123 | 125 | 129 | 130 | 291 | 201 | 211 | 212 | 213 | 238 | 242 | 143 | 145 | 146 | 147 | 148 | 190 | 217 | 221 | 264 | |||
| RVA/Vaccine/USA/RotaTeq SC2-9/1992/G2P[5] | A | N | S | D | E | W | E | N | Q | D | T | M | N | K | Q | D | V | S | N | S | R | D | N | T | S | D | I | S | G | ||
| RVA/Human-tc/USA/DS-1/1976/G2P[4] | A | N | S | D | E | W | E | N | Q | D | T | M | N | K | Q | D | V | D* | N | S | R | D | N | T | S | D | I | S | G | ||
| RVA/Human-tc/CHN/TB-Chen/1996/G2P[4] | A | N | S | D | E | W | E | N | Q | D | N | V | N | K | Q | D | V | N* | N | N* | R | D | N | T | S | D | I | S | G | ||
| RVA/Human-wt/BGN/MMC88/2005/G2P[4] | T* | N | S | N* | E | W | E | N | Q | D | T | M | D* | K | Q | D | V | D* | N | N* | R | D | N | T | S | D | I | S | G | ||
| RVA/Human-wt/BGN/J306/2010/G2P[4] | T* | N | S | N* | E | W | E | N | Q | D | T | M | D* | K | Q | D | V | D* | N | N* | R | D | N | T | S | D | I | S | G | ||
| RVA/Human-wt/BGN/J303/2010/G2P[4] | T* | N | S | N* | E | W | E | N | Q | D | T | M | D* | K | Q | D | V | D* | N | N* | R | D | N | T | S | D | I | S | G | ||
| RVA/Human-wt/BGN/J300/2010/G2P[4] | T* | N | S | N* | E | W | E | N | Q | D | T | M | D* | K | Q | D | V | D* | N | N* | R | D | N | T | S | D | I | S | G | ||
| RVA/Human-wt/BGN/J266/2010/G2P[4] | T* | N | S | N* | E | W | E | N | Q | D | T | M | D* | K | Q | D | V | D* | N | N* | R | D | N | T | S | D | I | S | G | ||
| RVA/Human-wt/BGN/J265/2010/G2P[4] | T* | N | S | N* | E | W | E | N | Q | D | T | M | D* | K | Q | D | V | D* | N | N* | R | D | N | T | S | D | I | S | G | ||
| RVA/Human-wt/BGN/J263/2010/G2P[4] | T* | N | S | N* | E | W | E | N | Q | D | T | M | D* | K | Q | D | V | D* | N | N* | R | D | N | T | S | D | I | S | G | ||
| RVA/Human-wt/BGN/J253/2010/G2P[4] | T* | N | S | N* | E | W | E | N | Q | D | T | M | N | K | Q | D | V | D* | N | N* | R | D | N | T | S | D | I | T* | G | ||
| RVA/Human-wt/BGN/J251/2010/G2P[4] | T* | N | S | N* | E | W | E | N | Q | D | T | M | N | K | Q | D | V | D* | N | N* | R | D | N | T | S | D | I | S | G | ||
| RVA/Human-wt/BGN/M334/2013/G2P[4] | T* | N | S | N* | E | W | E | N | Q | D | T | M | D* | K | Q | D | V | D* | N | N* | R | D | N | T | S | D | I | S | G | ||
| RVA/Human-wt/BGN/M315/2013/G2P[4] | T* | N | S | N* | E | W | E | N | Q | D | T | M | D* | K | Q | D | V | D* | N | N* | R | D | N | T | S | D | I | S | G | ||
| RVA/Human-wt/BGN/M313/2013/G2P[4] | T* | I* | S | N* | V* | W | E | N | Q | D | T | M | D* | K | Q | D | V | D* | N | N* | R | D | N | T | S | D | I | S | G | ||
| RVA/Human-wt/BGN/M312/2013/G2P[4] | T* | N | S | N* | E | W | E | N | Q | D | T | M | D* | K | Q | D | V | D* | N | N* | R | D | N | T | S | D | I | S | G | ||
| RVA/Human-wt/BGN/M310/2013/G2P[4] | T* | N | S | N* | E | W | E | N | Q | D | T | M | D* | K | Q | D | V | D* | N | N* | R | D | N | T | S | D | I | S | G | ||
| RVA/Human-wt/BGN/M292/2013/G2P[4] | T* | N | S | N* | E | W | E | N | Q | D | T | M | D* | K | Q | D | V | D* | N | N* | R | D | N | T | S | D | I | S | G | ||
| RVA/Human-wt/BGN/M289/2013/G2P[4] | T* | N | S | N* | E | W | E | N | Q | D | T | M | D* | K | Q | D | V | D* | N | N* | R | D | N | T | S | D | V* | A* | G | ||
| RVA/Human-wt/BGN/M282/2013/G2P[4] | T* | N | S | N* | E | W | E | N | Q | D | T | M | D* | K | Q | D | V | D* | N | N* | R | D | N | T | S | D | I | S | G | ||
*
Residues that differ from those of RotaTeq™ (G2 component).